Mom's Story

A discussion about Mom's Story and MS…

Archive for the month “December, 2013”

Multiple sclerosis cases hit 2.3 mln worldwide

(Reuters) – The number of people living with multiple sclerosis around the world has increased by 10 percent in the past five years to 2.3 million, according to the most extensive survey of the disease to date.

The debilitating neurological condition, which affects twice as many women as men, is found in every region of the world, although prevalence rates vary widely.

Multiple sclerosis (MS) is most common in North America and Europe, at 140 and 108 cases per 100,000 respectively, while in sub-Saharan Africa the rate is just 2.1 per 100,000, the Multiple Sclerosis International Federation’s Atlas of MS 2013 showed on Wednesday.

The atlas also confirmed that MS occurs significantly more in countries at high latitude, with Sweden having the highest rate in Europe and Argentina having more cases than countries further north in Latin America.

The reason for the link to high latitudes is unclear but some scientists have suggested that exposure to sunlight may reduce the incidence of the disease.

The survey found a big increases in the number of medical experts trained to diagnose MS and help patients with treatment, while the number of magnetic resonance imaging (MRI) machines available to carry out scans has doubled in emerging countries.

But huge disparities remain when it comes to access to modern disease-modifying drugs.

MS medicine has seen a number of advances in recent years, particularly with the introduction of a new generation of oral therapies such as Novartis’ Gilenya, Biogen Idec’s Tecfidera and Sanofi’s Aubagio.

These medicines offer an effective alternative to older disease-modifying treatments that are given by injection.

The survey found that injectable drugs like Biogen’s Avonex and Teva’s Copaxone were partly or fully funded in 96 percent of high-income countries, while Gilenya was available in 76 percent.

However, none of these drugs was available under government programmes in low-income countries. (Reporting by Ben Hirschler; Editing by Alistair Lyon)

Advertisements

Trial hints that a vaccine used to prevent tuberculosis may open a new treatment approach to preventing or treating MS

Researchers in Italy provide preliminary evidence that a vaccine used in some parts of the world to prevent tuberculosis, called Bacille Calmette-Guérin (BCG), may help people who exhibit early signs of possible MS from developing full-blown, definite MS. Additional, larger trials would be needed to determine the safety and effectiveness of this approach. Dr. Giovanni Ristori and colleagues at the University of Rome and other institutions recently reported their results in Neurology. The study was funded by the Italian Ministry of Health, the Italian MS Foundation, and other agencies.

Background: MS often begins with an initial neurological attack called “clinically isolated syndrome” (CIS). Many with CIS experience additional attacks and are eventually diagnosed with clinically defined MS. Dr. Ristori and colleagues conducted a small clinical study to see if the BCG vaccine could prevent people with CIS from developing clinically definite MS. BCG is a vaccine that is prepared from a strain of weakened bovine (cow) tuberculosis bacteria, and while commonly used in developing countries, is not approved for preventing tuberculosis in the United States.

The study: The investigators performed a double-blind, placebo-controlled clinical trial in which 73 participants with CIS received either the BCG vaccine or a sham injection (no vaccine), then after 6 months all participants received one year of interferon beta-1a, which was followed by whatever disease-modifying therapy recommended by their physicians. Participants and researchers were unaware of the assignment to a particular group. All told, 33 people received a single injection of the vaccine and 40 received the sham injection.

At six months after the injection, those who received the real vaccine had fewer active brain MRI lesions (an average of 3.1 lesions) consistent with MS, compared to those who had received the sham injections (an average of 6.6 lesions), suggesting a decrease in disease activity. Five years after completing the study, those who had been vaccinated were less likely to have experienced relapses, and the diagnosis of clinically definite MS, than those who received the sham injection: 58% of vaccinated participants were free of relapses compared to 30% of sham-injected participants. No adverse events were seen except an injection site reaction in three vaccinated people. No major adverse events were noted.

How BCG vaccination helped to prevent MS relapses in this study is not known. One idea is that vaccination alters the function of the immune system to decrease the ability of the immune system to attack the brain. In this study, the contribution of disease-modifying therapies in the results is unclear.

Comment: This small study provides intriguing evidence for a potentially beneficial effect of BCG vaccination in curbing MS. In an accompanying editorial, Drs. Dennis Bourdette (Oregon Health & Science University) and Robert Naismith (Washington University) note that the safety of repeated administration of this live vaccine is unclear, and that clinicians should not use BCG to treat CIS or MS at this time. Larger trials of this or a similar approach and additional research into the reasons for the vaccination’s impact may lead to the development of a new strategy for preventing or treating MS.

 

Post Navigation